Indaptus Therapeutics Announces $24M Private Placement

What Happened

• Indaptus Therapeutics, Inc. announced on September 8, 2026 that it entered a Stock Purchase Agreement with purchasers for a private placement of 20,338,974 shares of common stock, intended to generate approximately $24.0 million in gross proceeds. The filing (Form 8-K) was made on September 10, 2026.
• The per-share purchase price equals the “Nasdaq Minimum Price” (the lower of the prior trading day’s close or the five-day average close) plus $0.015. Closing is subject to customary conditions and must occur no later than the 15th business day after September 8, 2026.

Key Details

• Shares to be issued: 20,338,974 common shares (par value $0.01).
• Gross proceeds: approximately $24.0 million before expenses.
• Use of proceeds: working capital, research & development, and general corporate purposes; may include early-stage research and preclinical work on a potential neurotechnology/neural‑network device for certain sleep-related conditions.
• Registration: the company must use commercially reasonable efforts to file and get effective a registration statement to permit resale of the shares and keep it effective until the shares are no longer registrable under the Purchase Agreement.

Why It Matters

• This transaction will raise capital that Indaptus says will support R&D and operations; for investors it means dilution risk from the new shares but also additional funding to advance programs.
• The pricing tied to recent Nasdaq closing prices plus a small premium means the exact issuance price will depend on market levels at signing; closing remains subject to customary conditions.
• The company’s commitment to register the shares for resale may shorten resale restrictions for purchasers once the registration statement becomes effective.